Susquehanna International Group, LLP Annovis Bio, Inc. Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 164,558 shares of ANVS stock, worth $371,901. This represents 0.0% of its overall portfolio holdings.
Number of Shares
164,558
Previous 127,705
28.86%
Holding current value
$371,901
Previous $191,000
86.91%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ANVS
# of Institutions
50Shares Held
1.82MCall Options Held
102KPut Options Held
98.3K-
Vanguard Group Inc Valley Forge, PA697KShares$1.57 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$414,2280.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$227,6020.0% of portfolio
-
Merit Financial Group, LLC91.3KShares$206,3740.0% of portfolio
-
Marshall Wace, LLP London, X090.9KShares$205,4490.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.5M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...